← Back to Search

Monoclonal Antibodies

LY3872386 for Atopic Dermatitis/Eczema

Phase 1
Recruiting
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose up to 12 hours post dose on day 14 and day 30
Awards & highlights

Study Summary

This trial tests the safety and tolerance of an experimental drug, LY3872386, and prednisone in healthy people and people with atopic dermatitis. Blood tests will be used to study the body's response. The study lasts up to 85, 183, and 58 days for parts A, B, and C.

Who is the study for?
This trial is for healthy individuals and those with atopic dermatitis (eczema). Healthy participants must be of Japanese or Chinese descent as defined in the study, while those with eczema need to have struggled with current treatments. All must agree to use contraception if applicable.Check my eligibility
What is being tested?
The study tests LY3872386's safety and how it's processed by the body in both healthy people and those with eczema. Prednisone's safety will also be assessed in healthy subjects. The trial has three parts, each lasting different durations.See study design
What are the potential side effects?
Possible side effects include reactions typical of new medications such as skin irritation, digestive issues, changes in blood tests related to liver or kidney function, fatigue, and potential allergic reactions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose up to 12 hours post dose on day 14 and day 30
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose up to 12 hours post dose on day 14 and day 30 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs) and other non-serious adverse events (AEs) Considered by the Investigator to be Related to Study Drug Administration
Part B: Number of Participants with One or More TEAEs, SAEs and other non-serious AEs Considered by the Investigator to be Related to Study Drug Administration
Part C: Number of Participants with One or More TEAEs, SAEs and other non-serious AEs Considered by the Investigator to be Related to Study Drug Administration
Secondary outcome measures
Part A and B: Area Under the Concentration Versus Time Curve (AUC) of LY3872386
Part A and B: Maximum Observed Concentration (Cmax) of LY3872386
Part C: AUC of Prednisone and Prednisolone
+1 more

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Part C: PrednisoneExperimental Treatment1 Intervention
Prednisone administered orally in healthy participants.
Group II: Part B: LY3872386Experimental Treatment1 Intervention
Multiple doses of LY3872386 administered either IV or SC in participants with atopic dermatitis.
Group III: Part A: LY3872386Experimental Treatment1 Intervention
Single doses of LY3872386 administered either intravenously (IV) or subcutaneously (SC) in healthy participants.
Group IV: PlaceboPlacebo Group1 Intervention
Placebo administered either IV or SC.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Prednisone
2014
Completed Phase 4
~2370

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,620 Previous Clinical Trials
3,216,420 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,348 Previous Clinical Trials
415,566 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are individuals still able to enroll in this research endeavor?

"Clinicaltrials.gov confirms that sign-ups for this medical trial have ceased since November 1st, 2023 when the last update was posted. However, there are presently 1080 other clinical trials actively seeking patients across the globe."

Answered by AI

Who is able to partake in this scientific exploration?

"This research project is seeking healthy volunteers aged 18-65. In total, 179 participants will be accepted into this trial."

Answered by AI

What is the purpose of this exploration?

"According to the sponsor Eli Lilly and Company, this study is principally examining the Number of Participants with Adverse Events (AEs) related to Study Drug Administration over a span from Baseline through Day 85. Secondary endpoints include Area Under Curve (AUC), Cmax, AUC for LY3872386 as well Prednisone."

Answered by AI

What potential health risks do patients face when taking Part A: LY3872386?

"As this trial is at the Phase 1 stage, demonstrating limited information on both safety and efficacy, our team assigned Part A: LY3872386 a score of 1."

Answered by AI

Can citizens below the age of sixty participate in this trial?

"Eligibility for this trial is limited to those aged 18-65, with 157 trials open to younger patients and 583 studies available for seniors."

Answered by AI

Who else is applying?

What site did they apply to?
Paddington Testing Co, Inc
What portion of applicants met pre-screening criteria?
Did not meet criteria

Why did patients apply to this trial?

I'm looking for a study that needs healthy subjects. I am a medical student interested in science.
PatientReceived no prior treatments

What questions have other patients asked about this trial?

Will there be compensation?
PatientReceived 1 prior treatment
Recent research and studies
clinicaltrials.govStudy
A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis
2023. "A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06119529.
All > Atopic Dermatitis
~119 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top